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Abstract
Objective—Natriuretic peptide signaling is important in the regulation of blood pressure as well 
as in the growth of multiple cell types. To examine the role of natriuretic peptide signaling in 
atherosclerosis, we crossbred mice that lack natriuretic peptide receptor A (NPRA; Npr1−/−) with 
atherosclerosis-prone mice that lack apolipoprotein E (apoE; Apoe−/−).
Methods and Results—Doubly deficient Npr1−/− Apoe−/− mice have increased blood pressure 
relative to Npr1+/+ Apoe−/− mice (118±4 mm Hg compared with 108±2 mm Hg, P<0.05) that is 
coincident with a 64% greater atherosclerotic lesion size (P<0.005) and more advanced plaque 
morphology. Additionally, aortic medial thickness is increased by 52% in Npr1−/− Apoe−/− mice 
relative to Npr1+/+ Apoe−/− mice (P<0.0001). Npr1−/− Apoe−/− mice also have significantly greater 
cardiac mass (9.0±0.3 mg/g body weight) than either Npr1+/+ Apoe−/− mice (5.8±0.2 mg/g) or 
Npr1−/− Apoe+/+ mice (7.1±0.2 mg/g), suggesting that the lack of both NPRA and apoE 
synergistically enhances cardiac hypertrophy.
Conclusions—These data provide evidence that NPR1 is an atherosclerosis susceptibility locus 
and represents a potential link between atherosclerosis and cardiac hypertrophy. Our results also 
suggest roles for Npr1 as well as Apoe in regulation of hypertrophic cell growth.
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The natriuretic peptide system plays a critical role in regulating blood volume and blood 
pressure (BP).1,2 Atrial natriuretic peptide (ANP) and B-type natriuretic peptide are 
released mainly from the heart after wall stretch and act through natriuretic peptide receptor 
A (NPRA) in the kidneys and vasculature to induce natriuresis, diuresis, and vasorelaxation.
1,3,4 The importance of the natriuretic system in the etiology of hypertension is 
demonstrated in mice lacking NPRA (Npr1−/− mice), which have higher than normal BPs.5–
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7 Considerable evidence suggests that elevated BP might have a direct role in enhancing 
atherosclerotic lesion formation.8,9
In addition to the endocrine function in BP control, natriuretic peptides released from the 
heart also act in an autocrine/paracrine loop to inhibit hypertrophic growth of cardiac 
myocytes.10–12 In Npr1−/− mice, NPR signaling is absent, leading to a marked 
enhancement of cardiac hypertrophy that is independent of BP.11,13,14 Expression of ANP 
and B-type NP has also been detected in the vasculature,15 and in vitro evidence suggests 
that extracardiac autocrine/paracrine NP signaling might negatively regulate hypertrophic 
growth of both endothelial cells and vascular smooth muscle cells (VSMCs).16,17 Thus, 
through both endocrine and local functions, NPs likely play a role in the pathogenesis of 
atherosclerosis, and the NPR1 locus is therefore a potential candidate as a genetic risk factor 
for atherosclerosis.
Proving a direct causal role of mutations in a candidate gene in the pathogenesis of 
atherosclerosis is complicated by the homeostatic mechanisms that control BP, which might 
also play a role in atheroma formation. Mouse genetics is a powerful approach to elucidate 
the cause-effect relation behind hypertension and atherosclerosis and the interaction between 
these 2 pathological processes. Previously, we have shown that a lack of endothelial nitric 
oxide synthase results in increased BP and atherosclerotic plaque size in mice deficient for 
apolipoprotein E (apoE; Apoe−/− mice) that spontaneously develop atherosclerosis.18,19 
Here we have used a similar genetic approach to test the effects on atherosclerosis of a 
deficiency in NPRA. We demonstrate that mice lacking both NPRA and apoE 
(Npr1−/− Apoe−/−) have increased atherosclerosis compared with apoE-deficient mice that 
are of the wild-type for Npr1 (Npr1+/+ Apoe−/−). These mice also have increased BP as well 
as markedly greater aortic wall thickness relative to Npr1+/+ Apoe−/− mice, indicating a role 
for NP signaling in the development of atherosclerosis.
Methods
Mice
All mouse experiments were conducted under protocols approved by the Institutional 
Animal Care and Use Committee of the University of North Carolina. Mice were fed a 
normal chow diet. The Npr1−/− mice that were sixth generation–backcrossed to C57BL/6 
were bred with Apoe−/− mice that were also backcrossed at least 8 times to C57BL/6. 
Npr1+/− Apoe+/− mice were then crossed with Apoe−/− mice to generate Npr1+/− Apoe−/− 
mice. To minimize contributions to the phenotypes of the strain differences remaining in the 
experimental animals, most of the Npr1+/+ Apoe−/−, Npr1+/− Apoe−/−, and Npr1−/− Apoe−/− 
mice used for the experiments were littermates of an intercross between Npr1+/− Apoe−/− 
mice. An intercross between Npr1+/− Apoe−/− mice and Npr1+/− Apoe+/+ yielded those of the 
Apoe+/− background used in the current experiments. Npr1 genotype was determined by 
multiplex polymerase chain reaction (PCR) with primer I (5′-GCA TGG TTC AGC TCT 
AAG AC-3′), primer II (5′-CTA ACC CTG TGA ACT GTA AGC-3′), and primer III (5′-
CCT TCA GTT ATC TAC ATC TGC-3′) at a concentration ratio of 2:1:4. PCR with 
primers I and II amplifies a 550-bp fragment corresponding to the inactivated Npr1 gene, 
whereas PCR with primers I and III amplifies a 350-bp fragment indicative of the wild-type 
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Npr1 gene. Apoe genotype was determined by multiplex PCR with primer I (5′-AGA ACT 
GAC GTG AGT GTC CA-3′), primer II (5′-GTT CCC AGA AGT TGA GAA GC-3′), and 
primer III (5′-CTT CCT CGT GCT TTA CGG TA-3′) at a concentration ratio of 1:2:1. A 
300-bp product indicated the wild-type Apoe gene, and a 220-bp product indicated the 
inactivated locus.
Plasma Analyses
Plasma ANP level was measured by radioimmunoassay as previously described,8 and total 
cholesterol and triglycerides were measured by colorimetric assay (Sigma). HDL cholesterol 
was measured after removing apoB-containing lipoproteins by precipitation with 
polyethylene glycol. Plasma creatinine was measured by using a VT250 chemical analyzer 
(Johnson & Johnson).
BP Analysis
BPs were measured by the noninvasive tail-cuff method20 on conscious, restrained mice 3 
to 4 months of age. The BP of each mouse was the average of the daily means of 6 
consecutive days measured with two machines, each with 4 channels (Visitech). Each mouse 
was subjected to a total of 40 inflations (4 trials of 10 inflations) per day on a different 
channel each day. The first trial of 10 inflations allowed the mouse to warm up and 
acclimate to the cuff; these data were discarded. Data from the next 3 trials, each of 10 
inflations, were recorded. Daily means were calculated from the means of the 3 trials per 
day.
Atherosclerotic Lesion Analysis
Animals were euthanized with an overdose of 2,2,2-tribromoethanol at 4 months of age, and 
the vascular tree was perfused either with 4% paraformaldehyde in phosphate-buffered 
saline or with phosphate-buffered saline under physiological pressure. Segments of the 
aortic sinus were embedded, sectioned, and stained as described previously.21 Plaque size 
was measured with NIH IMAGE, version 1.59, and the average of the 4 sections chosen by 
strict anatomic criteria was taken as the mean lesion size for each animal. To evaluate 
plaque formation in other parts of the aorta, the aortic tree was dissected free of surrounding 
tissue and examined under a dissection microscope.
Media Thickness of Aorta and Cardiac Mass Measurements
Cross sections of aorta immediately superior to the aortic sinus and containing no 
atherosclerotic plaques were used to measure the thickness of the tunica media of the 
ascending aorta of each animal. Medial area was determined by tracing the area between the 
internal elastic lamina and external elastic lamina of the vessel with NIH IMAGE, version 1.59, 
to represent the average wall thickness. For cardiac mass measurements, hearts were excised 
after whole-body perfusion, blotted dry, and weighed.
Statistical Analysis
All data are expressed as mean±SE. ANOVA with JMP statistical software (SAS Institute) 
was used for the main data analysis, and probability values are from the F test unless 
Alexander et al. Page 3






















otherwise stated. Means of Npr1−/− and Npr1+/+ mice and means between Npr1+/− and 
Npr1+/+ mice were compared with Tukey's honestly significant difference test. Lesion size 
was analyzed by 2-way ANOVA with sex and genotype as the 2 factors. BP, medial 
thickness of aorta, and heart weight per body weight (HW/BW) did not differ by sex, and 
thus, data from males and females were analyzed together. Effect of sex and BP on the 
lesion sizes in Npr1+/− Apoe+/− and Npr1+/− Apoe+/− mice was estimated by linear regression 
models.
Results
Npr1−/− Mice Have Decreased Survival During the Neonatal Period
Doubly homozygous Npr1−/− Apoe−/− mice were born at the expected frequency from 
Npr1+/− Apoe−/− × Npr1+/− Apoe−/− mating, as judged by the genotypes of day 1 pups (24 
Npr1−/− Apoe−/−, 62 Npr1+/− Apoe−/−, and 34 Npr1+/+ Apoe−/−; P>0.39 by χ2 analysis after 
assuming a 1:2:1 ratio). However, at weaning (21 days of age), the number of 
Npr1−/− Apoe−/− mice was significantly reduced compared with Npr1+/− Apoe−/− and 
Npr1+/+ Apoe−/− mice (12:106:59, P<0.0001 by χ2 analysis). This early death phenomenon 
is due to Npr1 deficiency rather than Apoe deficiency or a combination thereof, because 
Npr1−/− Apoe+/+ mice also had decreased survival by day 21 compared with Npr1+/− Apoe+/+ 
and Npr1+/+ Apoe+/+ mice (4:33:20, P<0.01 by χ2 analysis) on the C57BL/6 background. 
Both Npr1−/− Apoe−/− and Npr1−/− Apoe+/+ mice that survived beyond 21 days of age 
appeared to have longevity similar to that of Npr1+/+ Apoe−/− and Npr1+/+ Apoe+/+ mice. 
Thus, the Npr1 genotype–dependent death was limited to a window soon after birth, but its 
cause was not evident in either gross or histologic examination of 1- to 3-day-old pups (not 
shown).
Npr1−/−Apoe−/− Mice Have Increased BP Compared With Npr1+/+ Apoe−/− Mice
Lack of NPRA causes increased BP in mice, and Npr1−/− Apoe−/− mice had elevated mean 
BPs relative to Npr1+/+ Apoe−/− mice (Figure 1A). There is an Npr1 gene-dosage effect 
(P<0.01) on BP in mice, because Npr1+/− Apoe−/− mice had an intermediate BP, but the 
difference between Npr1+/+ Apoe−/− and Npr1+/− Apoe−/− mice did not reach significance.
There was also an Npr1 gene-dosage effect on plasma ANP levels, because Npr1−/− Apoe−/− 
mice had significantly higher plasma ANP levels compared with Npr1+/+ Apoe−/− mice 
(P<0.002; Figure 1B).
Atherosclerotic Plaques in Npr1−/− Apoe−/− Mice Are Increased in Size and Complexity
Npr1−/− Apoe−/− mice had larger average lesion sizes within the proximal aorta compared 
with Npr1+/+ Apoe−/− mice (Figure 2A). Consistent with previous observations, female 
Apoe−/− mice had larger average lesion sizes than did males for all Npr1 genotypes. When 
sex was taken into consideration, the Npr1−/− Apoe−/− mice had, on average, 64% larger 
plaques than did Npr1+/+ Apoe−/− mice, and the effect of Npr1 genotype was significant 
(P<0.001 by 2-way ANOVA).
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In addition to increased lesion size, plaques in Npr1−/− Apoe−/− mice were more complex 
than those in Npr1+/+ Apoe−/− mice, with, on average notably, larger and more developed 
fibrous caps and a greater frequency of cholesterol clefts and calcifications (A and C in 
Figure 3). In contrast, typical lesions present in Npr1+/+ Apoe−/− mice had less developed 
fibrous caps and contained acellular and lipid-rich cores (B and D). The coronary ostia of 
Npr1−/− Apoe−/− mice also contained large lesions. Additionally, lesions are more prominent 
within the right carotid artery and within the aortic arch of Npr1−/− Apoe−/− compared with 
Npr1+/+ Apoe−/− mice, in which lesions were limited mainly to the aortic sinus (data not 
shown). These observations indicate an acceleration of the early stages of plaque 
development in Npr1−/− Apoe−/− mice.
This increase in lesion size, complexity, and distribution occurred in Npr1−/− Apoe−/− mice 
despite the lower plasma cholesterol and triglyceride levels relative to Npr1+/+ Apoe−/− mice 
(Table 1). In parallel with the reduction in total cholesterol, the levels of HDL cholesterol 
were also significantly lower in Npr1−/− Apoe−/− mice than in Npr1+/+ Apoe−/− mice. The 
plasma lipoprotein distribution analysis by fast liquid column chromatography showed an 
equal reduction in all classes of lipoprotein fractions (not shown). This difference in plasma 
lipid levels was not due to changes in blood volume, because hematocrit values were very 
similar between Npr1−/− Apoe−/− and Npr1+/+ Apoe−/− mice (Table 1).
Npr1−/− Apoe−/− Mice Have Increased Medial Thickness of the Aorta
Examination of the aorta proximal to the aortic sinus revealed that Npr1−/− Apoe−/− mice had 
thicker aortic walls than did Npr1+/+ Apoe−/− mice. The increase in wall thickness of the 
tunica media was pervasive and largely uniform throughout all 360° of the sectioned aorta 
and was due to marked hypertrophy of VSMCs (Figure 3, E and F).
The aortic sections free of noticeable atherosclerotic plaques were used for morphometric 
analysis. Ascending aortas of Npr1−/− Apoe−/− mice had larger medial areas than did those 
of Npr1+/+ Apoe−/− mice (P<0.0001, Figure 2B). There appeared to be a threshold rather 
than a gene-dosage effect of the Npr1 genotype, because Npr1+/− Apoe−/− mice had a mean 
area of 164±13×103 μm2 (n=9), similar to that for Npr1+/+ Apoe−/− mice. The observed 
increase in medial area was not due to differences in lumen size, because lumen sizes were 
nearly equal for Npr1−/− Apoe−/− and Npr1+/+ Apoe−/− mice (681±62×103 μm2 vs 
599±55×103 μm2, respectively [not significant]). Moreover, medial area was also increased 
in Npr1−/− mice on an Apoe+/− background, which did not develop atherosclerotic lesions 
(P<0.01, Figure 2B).
Both Npr1−/− and Apoe−/− Contribute to Cardiac Hypertrophy in Adult Mice
Consistent with our earlier observation that Npr1−/− mice had significant cardiac 
hypertrophy,11 Npr1−/− Apoe−/− mice had increased cardiac mass compared with 
Npr1+/+ Apoe−/− mice, as determined by their HW/BW at 4 months of age (P<0.0001, 
Figure 4A). There was also an Npr1 gene-dosage effect, because cardiac mass in 
Npr1+/− Apoe−/− mice was significantly different from that in both Npr1−/− Apoe−/− and 
Npr1+/+ Apoe−/− mice (P<0.0001). The gene-dosage effect of Npr1 was also present in mice 
that were wild-type for Apoe, because both Npr1−/− ApoE+/+ and Npr1+/− Apoe+/+ mice had 
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significantly larger cardiac mass than did Npr1+/+ Apoe+/+ mice (P<0.0001). These data 
together show a significant effect of Npr1 genotype on HW/BW that was evident in mice on 
both Apoe−/− and Apoe+/+ backgrounds (P<0.0001, 2-way ANOVA).
In addition to the Npr1 genotype effect on cardiac mass, there was also a significant Apoe 
genotype effect (P<0.0001, 2-way ANOVA), because Apoe−/− mice had greater HW/BW 
than did Apoe+/+ mice for all Npr1 genotypes at 4 months of age (Figure 4A). For instance, 
Npr1+/+ Apoe−/− mice had moderately but significantly greater cardiac mass than did 
Npr1+/+ Apoe+/+ mice (P<0.01), and Npr1+/− Apoe−/− mice had an ≈9% greater cardiac 
mass than did Npr1+/− Apoe+/+ mice (P=0.10). The Apoe effect was most dramatic in 
Npr1−/− Apoe−/− mice, which had 27% greater cardiac mass than did Npr1−/− Apoe+/+ mice 
(P<0.0001), suggesting a synergistic effect of Npr1 and Apoe in the pathogenesis of cardiac 
hypertrophy. Under light microscopy, Npr1−/− Apoe−/− hearts revealed enlargement of 
individual cardiac myocytes relative to Npr1+/+ Apoe−/− and Npr1+/+ Apoe+/+ hearts (data 
not shown), implicating classically defined cardiac hypertrophy in the synergistic increase in 
cardiac mass found in doubly deficient mice. Interestingly, whereas the Npr1−/− mice had 
increased cardiac mass at birth,11 the effect of apoE deficiency on HW was not present in 
newborn pups. Five-dayold Npr1−/− Apoe−/− pups had higher HW/BW than did 
Npr1+/+ Apoe−/− mice (P<0.05), but there was no Apoe genotypic effect at this early age, 
because, for instance, Npr1−/− Apoe−/− pups did not have greater HW/BW than did 
Npr1−/− Apoe+/+ pups (Figure 4B).
Finally, Npr1−/− Apoe−/− mice had a significantly higher kidney weight/BW (P<0.005) than 
did Npr1+/+ Apoe−/− mice, but there was no difference in plasma creatinine levels, indicating 
that their renal function was normal (Table 1).
Discussion
Our genetic approach revealed that the lack of Npr1 increases BP, atherosclerotic lesion 
size, and aortic medial area in Apoe−/− mice. Given that atherosclerosis is increased in mice 
with hypertension from other causes,18,22–25 increased BP likely contributes to 
atherogenesis in Npr1−/− Apoe−/− mice. However, because NPRA has intrinsic growth-
inhibitory and antimigratory properties in vitro in endothelial cells and VSMCs,26,27 
enhanced atherosclerosis in Npr1−/− Apoe−/− mice could be due to the loss of local NP 
signaling. Casco et al15 have reported increased expression of all 3 NPs and their receptors, 
except for NPRA in human coronary arteries with atherosclerosis. These observations 
support a possibility that an enhanced NP system is actively modulating the progression of 
atherosclerosis. We found that circulating ANP levels were higher in Npr1−/− Apoe−/− mice 
than in Npr1+/+ Apoe−/− mice (Figure 1B) and therefore, that NP signaling through receptors 
other than NPRA might be enhanced in the Npr1−/− Apoe−/− aorta. Despite this possible 
enhancement, however, atherosclerosis was increased in Npr1−/− Apoe−/− mice. Because of a 
high incidence of postnatal death of Npr1−/− Apoe−/− mice, we were unable to investigate the 
relative contributions of the physical BP effects and the direct effects of lack of NPRA in the 
aorta to the enhanced atherosclerosis in these mice. Mice with SMC-selective deletion of 
Npr1, such as those recently reported,28 could help dissociate the direct and indirect effects 
on atherosclerosis of the lack of NPRA.
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We were also interested in the effects of heterozygous loss of the Npr1 gene, because a 
quantitative reduction in NPRA function is more likely than is a total loss of function in the 
human population. We found that neither BP nor plaque size differed significantly between 
Npr1+/− Apoe−/− and Npr1+/+ Apoe−/− mice. Nevertheless, analysis of the 34 mice (16 
females and 18 males) in which BP was also measured indicates that the BP of individual 
animals and their sex together contributed approximately equally to 48% of the overall 
variance in lesion size (P<0.0001 for sex effect, P<0.0005 for BP effect). The regression 
analysis in Figure 5 shows that BP explains ≈30% of the variance in lesion size within 
females as well as within males. A substantial proportion of the variance remains 
unaccounted for. Plasma cholesterol levels and heart rates did not contribute significantly to 
the lesion size variance among these mice. Other potential factors include birth weight, litter 
size, and seasonal changes, but these were not tested.
Intima-media thickening of the aorta and other large vessels is associated with hypertension 
in humans and is an indicator of future cardiovascular events, including those linked to 
atherosclerosis.29,30 It is unlikely, however, that the increased wall thickness seen in 
Npr1−/− mice is due solely to increased BP, and indeed, there were no significant 
contributions of BP to the wall thickness variance in individual animals among the 
Npr1+/− Apoe−/− and Npr1+/+ Apoe−/− mice (n=17). In humans, a BP elevation of 25 mm Hg 
above normal is associated with increased carotid intima-media thickness of only 6% to 
19%.31,32 By contrast, our Npr1−/− Apoe−/− mice had a roughly 59% greater medial 
thickness than did Npr1+/+ Apoe−/− mice with a 10–mm Hg difference in BP. As suggested 
in vitro26,27 but not confirmed in vivo, lack of antihypertrophic autocrine/paracrine 
signaling in aortic SMCs likely contributes to the observed increase in medial area of 
Npr1−/− Apoe−/− mice. The extracardiac role for antihypertrophic NPRA signaling highlights 
the importance of this molecule in the growth control of VSMCs. Previous data have shown 
that NP signaling can negatively regulate the hypertrophic growth of cardiomyocytes in 
vitro,10 and the lack of NPRA increases cardiac hypertrophy.5,7,13 Our study confirms 
these effects of Npr1 on cardiac hypertrophy on both wild-type and Apoe−/− backgrounds. 
Recent human studies have found an association between left ventricular hypertrophy and 
intima-media thickness of the carotid and femoral arteries that is independent of BP.33,34 
Our data indicate that the Npr1 gene, though likely not alone in this category, could 
represent a link between these 2 associated conditions in humans. In fact, a BP-independent 
link between atherosclerosis and cardiac hypertrophy has been proposed to involve the 
progrowth activity of angiotensin II,35 against which natriuretic signaling could act in both 
VSMCs and cardiomyocytes.
In addition to the effects of NPRA on cardiac hypertrophy, our results also indicate a 
potential role of apoE in the development of cardiac hypertrophy. Although Apoe−/− mice 
are more susceptible than wild-type mice to cardiac hypertrophy induced by chronic 
constriction of the aorta28 and relatively small increases of their cardiac mass with age have 
been observed,36,37 the current study is the first to demonstrate a direct Apoe−/− genotype 
effect on cardiac hypertrophy that is synergistic with the effect of NPRA. Given the 
importance of apoE in lipid transport, apoE might exert its effects directly on the heart, 
facilitating fatty acid uptake and oxidation, the primary means of energy production in the 
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postfetal heart.38 Supporting this possibility, cardiac hypertrophy in Apoe−/− mice is not 
observed by 5 days of age (at or just before the energy production shift) but manifests only 
after the heart increases its demand for fatty acids. Alternatively, the observed Apoe 
genotype effect on cardiac mass might be not due to Apoe itself but to 129/Ola-derived 
genes that are closely linked to Apoe and differ functionally from their C57BL/6 
counterparts. Genes for dystrophia myotonica–protein kinase, calmodulin 3, and cardiac 
troponin I are among the potential candidates. In either case, the observed synergistic effect 
on cardiac hypertrophy in Npr1−/− Apoe−/− mice is likely due to growth stimuli that cannot 
be curtailed by NP signaling. Further work is required to determine the mechanisms behind 
the Apoe genotype effects on cardiac hypertrophy suggested by our genetic models.
In conclusion, our results from mice deficient in apoE and NPRA indicate that quantitative 
changes in functional Npr1 gene expression in humans could enhance atherosclerosis as well 
as cardiac hypertrophy. They also suggest that genetic alterations in the Apoe gene could 
enhance not only atherogenesis but also cardiac hypertrophy through as-yet-undetermined 
mechanisms.
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Npr1 genotype effect on BP (A) and plasma ANP levels (B). All animals were on the 
Apoe−/− background. Values in squares at the bottom of bars indicate number of animals, 
and values above bars are mean values. P<0.02 and P<0.006 by ANOVA for the effect of 
genotype on BP and on plasma ANP levels, respectively. Error bars represent SE. *P<0.02 
vs Npr1+/+ by Tukey's honestly significant difference test.
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A, Atherosclerotic plaque size within the aortic sinus. All mice were on the Apoe−/− 
background. Values in squares at the bottom of bars indicate number of animals, and values 
above the bars are mean area. Error bars represent SE. P<0.001 for Npr1 effect, and 
P<0.0001 for sex effect by ANOVA. *P<0.005 vs Npr1+/+ males by Tukey's . (B), Areas of 
the tunica media of the ascending aorta of Npr1−/− and Npr1+/+ mice. P<0.0001 for Npr1 
effects on both Apoe−/− and Apoe+/− backgrounds by ANOVA. There is no significant Apoe 
geno-type effect. *, P<0.0005 and **, P<0.03 versus Npr1+/+ by Tukey's honestly 
significant difference test.
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Representative light photomicrographs of proximal aortas of Npr1−/− (A, C, E) and Npr1+/+ 
(B, D, F) mice on an Apoe−/− background. Sections are stained with Sudan IV and 
counterstained with hematoxylin. A and B, Coronary ostia (yellow arrows) of female mice. 
C and D, Aortic roots of male mice. Black arrowheads point to well-developed fibrous caps 
in Npr1−/− mice compared with thin caps in Npr1+/+ mice. E and F, Medial layers from 
ascending aortas of male mice.
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HW/BW in 4-month-old (A) and 5-day-old (B) Npr1 mutants on Apoe−/− and Apoe+/+ 
backgrounds. Values in squares at the bottom of bars indicate number of animals, and mean 
values are listed above the bars. Error bars represent SE. P<0.0001 by ANOVA for Npr1 
genotypic effect in both adults and pups. Apoe genotype effect is P<0.0001 by ANOVA in 
adults but not significant in pups. *P<0.005 and **P<0.05 vs Npr+/+; P<0.0005 vs Apoe+/+ 
by Tukey's honestly significant difference test.
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Correlation between BP and relative lesion size in individual Npr1+/– Apoe−/− and 
Npr1+/+ Apoe−/− mice. Squares represent males and circles represent females. Open symbols 
are Npr1+/− Apoe−/− mice, and closed symbols are Npr1+/+Apoe−/− mice.
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